Bio-Pharmaceutical Industry
Jump to navigation
Jump to search
A Bio-Pharmaceutical Industry is a therapeutic industry associated with bio-synthesized drugs (that make use of biological sources).
- Context:
- It can be composed of Biopharmaceutical Orgs, such as: Biopharmaceutical Manufacturers, Biopharmacetical Research Orgs, Biopharmaceutical Service Orgs.
- …
- Example(s):
- Bayer AG.
- Bluepharma.
- …
- Counter-Example(s):
- See: Biopharmacology, Pharmacology, Pharmaceutical Drug, Semisynthesis, Biology, Total Synthesis, Vaccine, Whole Blood, Allergenic, Somatic Cell, Gene Therapy, Recombinant Proteins, Medical Wearable Device.
References
2021
- (Wikipedia, 2021) ⇒ https://en.wikipedia.org/wiki/Biopharmaceutical Retrieved:2021-10-24.
- A biopharmaceutical, also known as a biologic(al) medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, whole blood, blood components, allergenics, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living medicines used in cell therapy. Biologics can be composed of sugars, proteins, nucleic acids, or complex combinations of these substances, or may be living cells or tissues. They (or their precursors or components) are isolated from living sources—human, animal, plant, fungal, or microbial. They can be used in both human and animal medicine. Terminology surrounding biopharmaceuticals varies between groups and entities, with different terms referring to different subsets of therapeutics within the general biopharmaceutical category. Some regulatory agencies use the terms biological medicinal products or therapeutic biological product to refer specifically to engineered macromolecular products like protein- and nucleic acid-based drugs, distinguishing them from products like blood, blood components, or vaccines, which are usually extracted directly from a biological source. Specialty drugs, a recent classification of pharmaceuticals, are high-cost drugs that are often biologics. The European Medicines Agency uses the term advanced therapy medicinal products (ATMPs) for medicines for human use that are "based on genes, cells, or tissue engineering", including gene therapy medicines, somatic-cell therapy medicines, tissue-engineered medicines, and combinations thereof. Within EMA contexts, the term advanced therapies refers specifically to ATMPs, although that term is rather nonspecific outside those contexts. Gene-based and cellular biologics, for example, often are at the forefront of biomedicine and biomedical research, and may be used to treat a variety of medical conditions for which no other treatments are available. In some jurisdictions, biologics are regulated via different pathways from other small molecule drugs and medical devices.
Biopharmaceutics is pharmaceutics that works with biopharmaceuticals. Biopharmacology is the branch of pharmacology that studies biopharmaceuticals.
- A biopharmaceutical, also known as a biologic(al) medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, whole blood, blood components, allergenics, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living medicines used in cell therapy. Biologics can be composed of sugars, proteins, nucleic acids, or complex combinations of these substances, or may be living cells or tissues. They (or their precursors or components) are isolated from living sources—human, animal, plant, fungal, or microbial. They can be used in both human and animal medicine. Terminology surrounding biopharmaceuticals varies between groups and entities, with different terms referring to different subsets of therapeutics within the general biopharmaceutical category. Some regulatory agencies use the terms biological medicinal products or therapeutic biological product to refer specifically to engineered macromolecular products like protein- and nucleic acid-based drugs, distinguishing them from products like blood, blood components, or vaccines, which are usually extracted directly from a biological source. Specialty drugs, a recent classification of pharmaceuticals, are high-cost drugs that are often biologics. The European Medicines Agency uses the term advanced therapy medicinal products (ATMPs) for medicines for human use that are "based on genes, cells, or tissue engineering", including gene therapy medicines, somatic-cell therapy medicines, tissue-engineered medicines, and combinations thereof. Within EMA contexts, the term advanced therapies refers specifically to ATMPs, although that term is rather nonspecific outside those contexts. Gene-based and cellular biologics, for example, often are at the forefront of biomedicine and biomedical research, and may be used to treat a variety of medical conditions for which no other treatments are available. In some jurisdictions, biologics are regulated via different pathways from other small molecule drugs and medical devices.
2020
- https://www.qualio.com/blog/differences-between-biopharmaceutical-versus-pharmaceutical-startups
- QUOTE: ... The biopharmaceutical industry and pharmaceutical industry differ in several ways. The main difference comes down to product manufacturing. Biopharmaceutical products are manufactured in living organisms, including white blood cells or bacteria. On the flip side, pharmaceutical products are manufactured using chemical-based processes. Both of these product categories assist in the prevention and treatment of all communicable and non-communicable diseases, including infectious, genetic, and physiological diseases. All biopharmaceutical/pharmaceutical manufacturers must achieve rapid regulatory approval through all major governing bodies.
Here’s a complete summary of some of the other key differences between biopharmaceutical and pharmaceutical startups. ...
- QUOTE: ... The biopharmaceutical industry and pharmaceutical industry differ in several ways. The main difference comes down to product manufacturing. Biopharmaceutical products are manufactured in living organisms, including white blood cells or bacteria. On the flip side, pharmaceutical products are manufactured using chemical-based processes. Both of these product categories assist in the prevention and treatment of all communicable and non-communicable diseases, including infectious, genetic, and physiological diseases. All biopharmaceutical/pharmaceutical manufacturers must achieve rapid regulatory approval through all major governing bodies.